| Project/Area Number |
18K07266
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
西海 信 神戸大学, 医学研究科, 医学研究員 (20514706)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 代謝物バイオマーカー / 高リスクIPMN / 多重ロジスティック / メタボロミクス / 膵疾患 / IPMN / バイオマーカー / 代謝物 / 膵がん / 代謝 / 質量分析 |
|---|
| Outline of Final Research Achievements |
Although early detection of pancreatic cancer is difficult, it is known that detection and tracking of intraductal papillary mucinous neoplasm (IPMN) can contribute to early detection. In this study, we explored metabolite biomarkers for detection of IPMN and pancreatic cancer. Metabolites in the blood of 44 cases of pancreatic cancer, 15 cases of high-risk IPMN, and 46 cases of healthy subjects were analyzed by GC/MS, and a diagnostic formula combining methionine, arabinose, histidine, and lysine with BMI, ALP, and HbA1c was developed. The sensitivity of this diagnostic formula for pancreatic cancer/high-risk IPMN was 92% and the specificity was 90%.
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでCTやMRIなど大規模な検査が必要であったIPMNを血液バイオマーカーによって検出することができれば、より効率的に膵癌高リスク保因者を拾い上げることができ、膵癌の嘔気発見に寄与できる可能性がある。また疾病によってヒトの代謝環境が特異的に変化していることを示唆しており、疾患診断や治療効果予測、予後予測など幅広い応用が期待できる。
|
